Jyong Biotech Ltd. Participated in the 22nd Urological Association of Asia Congress to Display the Clinical Data for its Phase III Studies of BOTRESO and Phase II Study of MCS-8 (PCP)

Core Insights - Jyong Biotech Ltd. is a biotechnology company focused on developing plant-derived drugs for urinary system diseases, with a primary emphasis on the U.S., EU, and Asian markets [1][10] Group 1: Clinical Trials and Drug Development - The Phase III clinical trials for BOTRESO included two pivotal studies and two open-label extension studies, with results indicating significant improvement in lower urinary tract symptoms in the Asian subgroup compared to placebo [2] - BOTRESO is the first Taiwanese-developed oral botanical drug to receive IND approval from the U.S. FDA for Phase III trials, showcasing the company's innovative capabilities [4] - MCS-8 (PCP) demonstrated positive results in its Phase II trial, showing lower rates of positive prostate biopsies and high-grade prostate cancer compared to placebo, paving the way for further development [6] Group 2: Market Potential and Growth - The U.S. BPH patient population reached approximately 4.7 million in 2020, reflecting a 6.8% increase since 2017, while the global BPH patient count rose from 88.4 million in 2017 to 94.2 million in 2020 [5] - The global BPH drug market expanded from $3.7 billion in 2017 to $4.1 billion in 2020, with projections indicating it could reach $9.8 billion by 2026, highlighting significant growth potential [5] Group 3: Strategic Partnerships and Global Reach - Jyong Biotech maintains global patent coverage for BOTRESO and has signed multiple letters of intent and licensing agreements with international pharmaceutical partners to support global market entry [8] - The company is in discussions with global pharmaceutical partners for the further development of MCS-8, aiming to initiate large-scale Phase III trials involving thousands of participants [7]